Andrew Antoszyk is an Ophthalmology physician affiliated with Charlotte Eye Ear Nose & Throat Associates. OpenAlex indexes 91 publications with 7,611 citations (h-index 41); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6035 Fairview Rd
Charlotte, NC 282103256
Telephone
704-295-3000Provider last certified this registry record 23 Apr 2021.
Clinical trials
- Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab
Sponsor: Southeast Clinical Research Associates, LLC
- Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
Sponsor: Jaeb Center for Health Research
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Notal Vision, Inc.Program year20221 payment
- Apellis Pharmaceuticals, Inc.Program year20222 payments
- Genentech USA, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
81.5%Vascular Endothelial Growth Factor Inhibitor81.5%Aflibercept89%Bevacizumab11%Part B, office-administered≥163 patientsSensory organs
18.5%Antineovascularisation agents11.1%Brolucizumab-dbll100%Part B, office-administered≥15 patientsProstaglandin Analog3.1%Latanoprost100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 1987–1989 per NIH RePORTER. The latest:
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”